Main menu

Recent Pfizer Press Releases

10/17/14 4:38pm EDT
FDA Approves Abuse Deterrent Labeling for EMBEDA® (morphine sulfate and naltrexone hydrochloride) Extended-Release (ER) Capsules CII

EMBEDA is the first and only approved ER morphine specifically designed to deter oral and intranasal abuse when crushed

Pfizer Inc. (NYSE:PFE) announced today that the United States Food and Drug Administration (FDA) has approved an updated label for EMBEDA® (morphine sulfate and naltrexone hydrochloride) extended-release (ER) capsules, for oral use, CII, to include abuse-deterrence studies. The updated label states that EMBEDA has properties that are expected to reduce abuse via the oral and intranasal (i.e., snorting) routes when crushed. However, abuse of EMBEDA by these routes is still possible.

10/13/14 8:00am EDT
Pfizer Announces FDA Acceptance Of Palbociclib New Drug Application With Priority Review

NDA Requests Approval of Palbociclib as a First-Line Therapy in Combination with Letrozole for ER+, HER2- Advanced Breast Cancer

Pfizer Inc. today announced the New Drug Application (NDA) for palbociclib has been accepted for filing and granted Priority Review by the United States Food and Drug Administration (FDA).

10/10/14 8:00am EDT
Pfizer to Present New Data Evaluating Safety, Tolerability and Immunogenicity of its Investigational Staphylococcus aureus Vaccine Candidate at IDWeek 2014™

Rapid and sustained response in functional antibody titers observed following single-dose administration of a novel, investigational 4-antigen Staphylococcus aureus vaccine (SA4Ag) to healthy adults

Pfizer announced today that it will present data from a Phase 1/Phase 2 study evaluating the safety, tolerability and immunogenicity of a single-dose vaccine of Pfizer’s investigational 4-antigen Staphylococcus aureus (S. aureus) candidate vaccine (SA4Ag) in healthy adults.

10/8/14 8:30am EDT
Pfizer and Breast Cancer Leaders Join Together to Increase Understanding and Dispel Myths about Metastatic Breast Cancer

  • Metastatic breast cancer currently affects 150,000-250,000 people in the U.S. and remains an incurable condition1,2
  • New initiative aims to expand the breast cancer conversation to be more inclusive of metastatic disease

This October, Pfizer Inc. is uniting with leaders in the breast cancer community in a public call-to-action to expand the breast cancer dialogue to include metastatic breast cancer. This comes after a first-of-its-kind survey commissioned by Pfizer revealed that many people know little to nothing about metastatic breast cancer – the most advanced stage of breast cancer (Stage IV), in which cancer has spread beyond the breast to other organs in the body.2,3

10/8/14 8:00am EDT
Pfizer To Present Safety And Immunogenicity Data From A Phase 2 Study Of Its Investigational Meningococcal Group B Vaccine, Bivalent rLP2086, Co-Administered With A Licensed Human Papillomavirus Vaccine

Data From This Study Will Be Presented At IDWeek 2014™ In Philadelphia

Pfizer Inc. (NYSE:PFE) announced today it will present the results of a Phase 2, randomized study to evaluate co-administration of the company’s investigational meningococcal group B vaccine, bivalent recombinant LP2086 (rLP2086), with a licensed quadrivalent human papillomavirus vaccine (HPV4), at IDWeek 2014™ in Philadelphia. Data demonstrated immune responses to both vaccines were generated after concomitant administration of bivalent rLP2086 and HPV4.

9/29/14 8:00pm EDT
Pfizer And Kyowa Hakko Kirin To Collaborate On Immuno-Oncology Combination Study

Agreement to Combine Kyowa Hakko Kirin’s Anti-CCR4 Antibody Mogamulizumab and Pfizer’s investigational 4-1BB agonist (PF-05082566) in Clinical Study

Pfizer Inc.

9/25/14 8:00am EDT
Pfizer Completes Acquisition Of InnoPharma

Pfizer Inc. (NYSE:PFE) today announced that it has completed its acquisition of the pharmaceutical development company, InnoPharma, Inc., following receipt of United States (U.S.) regulatory approval from all government authorities required by the agreement and other closing conditions.

9/23/14 10:00am EDT
Pfizer Invites Public to View and Listen to Webcast of October 28 Conference Call with Analysts

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 28, 2014. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2014 Performance Report, to be issued that morning.


9/23/14 8:00am EDT
Kim Cattrall Encourages Women to Embrace Menopause with Style

Pfizer launches new campaign to inspire postmenopausal women to tune into their bodies

Every day, an estimated 6,000 women in the United States reach menopause.1 To inspire this growing pop

9/19/14 8:00am EDT
Pfizer Foundation Provides $2 Million In Grants To Support ‘Last-Mile’ Vaccine Coverage In Africa

  • Efforts in support of the United Nations Millennium Development Goal (MDG) 4 to reduce under-5 child mortality rate.
  • Programs designed to reach children in remote locations in five African countries.

The Pfizer Foundation today announced $2 million in grant funding for pilot programs to improve immunization coverage in Africa. The programs will focus on ‘last-mile’ interventions to reach underserved populations living in Ethiopia, Malawi, Rwanda, Uganda and Zambia.

9/3/14 10:00am EDT
Pfizer Invites the Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Geno Germano, Group President, Global Innovative Pharma Business, at the Morgan Stanley Global Healthcare Conference on Wednesday, September 10, 2014 at 12:55 p.m. Eastern Daylight Time.

8/28/14 1:15pm EDT
Pfizer and Protalix BioTherapeutics Announce FDA Approval of Pediatric Indication for ELELYSO™ (taliglucerase alfa) for Injection, for Intravenous Use for the Treatment of Type 1 Gaucher Disease

Pfizer Inc. (NYSE:PFE) and Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX, TASE:PLX) announced today that the U.S. Food and Drug Administration (FDA) approved ELELYSO™ (taliglucerase alfa) for injection for pediatric patients. ELELYSO is therefore now indicated for long-term enzyme replacement therapy (ERT) for adult and pediatric patients with a confirmed diagnosis of Type 1 Gaucher disease.

8/28/14 8:00am EDT
Pfizer’s Investigational Vaccine Candidate for Clostridium difficile Receives U.S. Food and Drug Administration Fast Track Designation

Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s investigational Clostridium difficile (C. difficile) vaccine candidate (PF-06425090). Currently in Phase 2 clinical development, the vaccine candidate is designed to prevent C. difficile-associated disease, which can include life-threatening diarrhea and pseudomembranous colitis.

8/26/14 8:00am EDT
Pfizer And Merck To Collaborate On Study Evaluating Novel Anti-Cancer Combination Regimen

Agreement to Combine Merck’s Investigational Anti-PD-1 Antibody Pembrolizumab and Pfizer’s Crizotinib (XALKORI®) in Clinical Trial

8/21/14 1:31pm EDT
U.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy

  • Eliquis demonstrated noninferiority in the primary efficacy endpoint of recurrent symptomatic venous thromboembolism (VTE) or VTE-related death versus enoxaparin/warfarin in the AMPLIFY trial
  • Eliquis demonstrated superiority in the primary safety endpoint of major bleeding versus enoxaparin/warfarin in the AMPLIFY trial

Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved a Supplemental New Drug Application (sNDA) for Eliquis for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. Combined, DVT and PE are known as VTE. It is estimated that every year, approximately 900,000 Americans are affected by DVT and PE.

8/20/14 8:00am EDT
Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis® (apixaban) at the ESC Congress 2014

  • Fourteen abstracts to be presented, including new analyses from the ARISTOTLE®, AMPLIFY® and AMPLIFY-EXT trials evaluating patients with nonvalvular atrial fibrillation (NVAF) and venous thromboembolism (VTE)
  • New global health economics and outcomes research (GHEOR) assessing Eliquis cost effectiveness and real-world comparative effectiveness research will also be presented

8/18/14 8:00am EDT
Pfizer Announces Submission of Palbociclib New Drug Application to the FDA

Pfizer Inc. today announced it has completed the submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for palbociclib. This NDA requests FDA approval of palbociclib, in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer who have not received previous systemic treatment for their advanced disease.